Paralysis, Unilateral, Vocal Cord
Conditions
Brief summary
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
Detailed description
The APrevent® VOIS is intended to be permanently implanted during a type I thyroplasty in individuals suffering from permanent unilateral vocal fold paralysis of various etiologies. Four post-operative follow-up visits are planned: Week 1 (± 7 days), Week 7 (-7/+28 days), Month 6 (-14/+28 days) and Month 12 (-14/+28 days). This 2-part study will consist of Part A to assess safety of the patients and the following Part B to assess the performance (effectiveness) of the investigational device. In Part A of the study 8 patients will be enrolled sequentially within three groups (N=1, N=2, N=5). After enrolment and 1st Follow-up Visit of each group, a Local Safety Board will review safety and study data. No preliminary/interim analysis of safety and effectiveness data will be performed before the end of the study.
Interventions
DEVICEAPrevent® VOIS-Implant
To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
Sponsors
APrevent Biotech GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study will consist of two parts to assess safety, and effectiveness of the investigational device. Part A (Safety): In total 8 patients will be enrolled sequentially in three groups (N=1, N=2, N=5). An interval of at least 7 days between the groups will be left to allow the safety board to review individual patient's safety and demographic data. After completion of the first four patients and all three groups in Part A, an independent Data Safety Monitoring Board (DSMB) will recommend the initiation of study Part B based on the review of the safety data. Part B: In Part B of the study, the remaining 22 patients of the study will be enrolled non-sequentially. Part A and B (Effectiveness Population) will include: The part A patients will also be used for the confirmatory testing of the primary endpoint. At the end of the study safety of the investigational device will be assessed on patients of part A and B together.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female patients between 18 and 80 years * Diagnosed with permanent UVFP and insufficient glottal closure * A significant voice disorder as measured by perceptual rating (Grade ≥2 GRBAS Scale) and Voice Handicap Index (VHI-30 score \>33) * Ability to comprehend the full nature and purpose of the study, including possible risks and side effects * Ability to co-operate with the Investigator and to comply with the requirements of the entire study * Availability to volunteer for the entire study duration, willing to adhere to all protocol requirements and willing and able to give informed consent for participation
Exclusion criteria
* Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the clinical investigation may influence the result of the clinical investigation, or the participant's ability to participate in the clinical investigation * Scheduled elective surgery or other procedures requiring general anaesthesia during clinical investigation * Bilateral vocal fold paralysis * Had injection medialization laryngoplasty with the injectable still being within the double length of the maximum resorption time frame as stated in their approval or as supported by literature. * Presence of structural vocal fold lesions such as polyp or nodules * Presence of oropharyngeal or laryngeal tumors * Patients with diagnosed severe obstructive sleep apnea (OSA) * Status post total cordectomy * Previous laryngeal framework surgery (any type of thyroplasty, arytenoid adduction) * Status post tracheostomy * Presence of acute systemic infection at time of screening or shortly before surgery * Significant non-laryngeal speech abnormality (severe dysarthria determined by a panel of trained speech therapists) * Severe coagulopathy * Females who are pregnant, lactating or planning pregnancy are excluded from the investigation * Patients with bil. Gr. III-IV hypertrophic tonsils * Diabetes mellitus with poor control and poor wound healing history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in G-Score from GRBAS-Scale | 7weeks | Change in G-Score from GRBAS-Scale from before to 7 weeks after permanent APrevent® VOIS implantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Maximum Phonation Time (MPT, unit seconds) from before to 7 weeks after permanent APrevent® VOIS implantation. | 7 weeks | MPT will be measured in seconds using a digital stop clock. The patient will be asked to say a prolonged vowel a for as long as possible after maximal inspiration. The best out of three trials in seconds will be chosen for comparison. |
Other
| Measure | Time frame | Description |
|---|---|---|
| R-Score from GRBAS-Scale from before to 7 weeks after permanent APrevent® VOIS implantation. | 7 weeks | R-Score from GRBAS-Scale from before to 7 weeks after permanent APrevent® VOIS implantation. |
| B-Score from GRBAS-Scale (range [0…3]) from before to 7 weeks after permanent APrevent® VOIS implantation | 7 weeks | B-Score from GRBAS-Scale from before to 7 weeks after permanent APrevent® VOIS implantation. |
Countries
Austria, Germany, United States
Contacts
Primary ContactBerit Schneider-Stickler, Prof
Backup ContactMatthias Leonhard, Dr
Outcome results
None listed